Immunotherapies for Acute Myeloid Leukemia

The efficacy of immunotherapeutic approaches in the treatment of different cancer types is becoming increasingly obvious, and immunotherapies in cancer treatment have experienced a significant breakthrough in the last few years. Immunotherapy encompasses several diverse treatment approaches, each of...

Full description

Saved in:
Bibliographic Details
Other Authors: Greiner, Jochen (Editor)
Format: Book Chapter
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
Subjects:
Online Access:Get Fullteks
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02752naaaa2200277uu 4500
001 doab_20_500_12854_68750
005 20210501
020 |a books978-3-03936-111-3 
020 |a 9783039361106 
020 |a 9783039361113 
024 7 |a 10.3390/books978-3-03936-111-3  |c doi 
041 0 |a English 
042 |a dc 
072 7 |a M  |2 bicssc 
100 1 |a Greiner, Jochen  |4 edt 
700 1 |a Greiner, Jochen  |4 oth 
245 1 0 |a Immunotherapies for Acute Myeloid Leukemia 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (162 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a The efficacy of immunotherapeutic approaches in the treatment of different cancer types is becoming increasingly obvious, and immunotherapies in cancer treatment have experienced a significant breakthrough in the last few years. Immunotherapy encompasses several diverse treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to boost or restore immune function in some manner. Consequently, T cell activating immunotherapeutic approaches like immune checkpoint inhibition, chimeric antigen receptor T cells (CARs), or bi-specific T cell activating antibodies are becoming increasingly important treatment strategies in different solid tumor types as well as in hematological malignancies. T cell responses against malignant cells play a major role in maintaining remission and prolonging overall survival in patients after allogeneic stem cell transplantation and donor lymphocyte infusions (DLI) due to the graft-versus-leukemia effect. In acute myeloid leukemia (AML) after intensive chemotherapy, most patients achieve complete remission; however, the overall survival for all AML patients, especially in elderly patients, is still relatively low. Immunotherapeutic approaches for AML patients might be options to reduce the relapse rate and improve overall survival. This Special Issue will focus on immunotherapeutic approaches in AML in established therapies, like the allogeneic stem cell transplantation including new concepts improving the graft-versus-leukemia effect, but also on new efforts to improve immune responses like adoptive T cell transfer, immune checkpoint inhibition, bi-specific antibodies, and CAR-T-cell approaches. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Medicine  |2 bicssc 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/2516  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/68750  |7 0  |z DOAB: description of the publication